Initial transcatheter thrombolysis for acute superior mesenteric venous thrombosis

Table 3 Treatment outcomes of acute superior mesenteric vein thrombosis patients n (%)

Outcome	Overall (n = 25)	Group 1 (n = 12)	Group 2 (n = 13)	P value
Morbidity
Bleeding	4 (16.0)	1 (8.3)	3 (23.1)	0.590
Wound infection	3 (12.0)	3 (25.0)	0 (0.0)	0.100
Acute kidney injury	4 (16.0)	2 (16.7)	2 (15.4)	1.000
Short bowel syndrome	5 (20.0)	5 (41.7)	0 (0.0)	0.020
Secondary portal hypertension	1 (4.0)	1 (8.3)	0 (0.0)	0.480
Cavernous transformation of the portal vein	2 (8.0)	2 (16.7)	0 (0.0)	0.220
Delayed or secondary operation	6 (24.0)	2 (16.7)	4 (30.8)	0.650
Bowel transmural necrosis	2 (8.0)	0 (0.0)	2 (15.4)	0.480
Bowel perforation	1 (4.0)	1 (8.3)	0 (0.0)	0.480
Bowel stricture	3 (12.0)	1 (8.3)	2 (15.4)	1.000
Laparoscopic surgery	4 (16.0)	0 (0.0)	4 (30.8)	0.100
Length of resection (cm)2	100 (range: 0, 155)	155 (105, 200)	0 (0, 65)	< 0.001
Time from treatment to symptom elimination1	12.52 ± 7.85	18.25 ± 7.69	7.23 ± 2.42	< 0.001
Time from admission to enteral or oral nutrition (d)1	14.48 ± 6.98	20.50 ± 5.13	8.92 ± 1.89	< 0.001
Duration of hospitalization in (d)1	31.28 ± 15.51	43.00 ± 13.77	20.46 ± 6.59	< 0.001
Total cost in RNB1	133895.20 ± 90996.47	200020.40 ± 91505.62	72785.60 ± 21828.16	0.001
< 30-d mortality	24 (96.0)	11 (91.7)	0 (0.0)	0.480
1-yr survival	21 (84.0)	9 (75.0)	12 (92.3)	0.320

¹Analysis was performed by t test;

²Mann-Whitney U test; or Fisher’s exact test.